NP mentioned IMMU today. I have been an investor in IMMU for many years. When a few years ago there was an attempt by business-wise incompetent management to sell the company for a fraction of It’s value, a shareholder revolt eventually blocked the sell and removed the management. The management was scientifically brilliant but they didn't know how to get their drug delivery molecule to market. The management change was the turning point for the company and led to the sell of the company this week for move that 40 times as much. Is a change of the management team going to be necessary for CYDY as well? I hope not since the chaos of an unfriendly change would further delay the making of Leronlimab available to patients who really need it today.